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Abstract
Background: We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months
of therapy in ovarian cancer.
Methods: A case series of 170 ovarian cancer patients treated at Cancer Treatment Centers of America. Based on
CA125 levels at baseline and 3 months, patients were classified into 4 groups: 1) Normal (0-35 U/ml) at baseline
and three months; 2) High (>35 U/ml) at baseline, normal at three months; 3) Normal at baseline, high at 3
months; 4) High at baseline and three months. Kaplan Meier method was used to calculate survival across the 4
categories.
Results: Of 170 patients, 36 were newly diagnosed while 134 had received prior treatment. 25 had stage I disease at
diagnosis, 15 stage II, 106 stage III and 14 stage IV. The median age at presentation was 54.2 years (range 23.1 - 82.5
years). At baseline, 31 patients had normal (0-35 U/ml) serum CA125 levels while 139 had high (>35 U/ml) levels. At
3 months, 59 had normal while 111 had high levels. Patients with a reduced CA125 at 3 months had a significantly
better survival than those with increased CA125 at 3 months. Patients with normal values of CA125 at both baseline
and 3 months had the best overall survival.
Conclusions: These data show that reduction in CA125 after 3 months of therapy is associated with better overall
survival in ovarian cancer. Patients without a significant decline in CA125 after 3 months of therapy have a
particularly poor prognosis.
Background
Ovarian cancer is the second most common gynecologic
malignancy in the United States, with approximately
22,200 new cases each year [1]. It is also the leading
cause of death from gynecologic cancers in the United
States [2]. The overall lifetime risk of developing ovarian
cancer for women in the United States is 1.4% to 1.8%.
This risk varies from 0.6% for women with no family
history, at least three term pregnancies, and four or
more years of oral contraceptive use, to 3.4% for nulli-
parous women with no oral contraceptive use. For
women with a family history, the lifetime risk for ovar-
ian cancer is estimated at 9.4% [3].
Ovarian cancer is often asymptomatic in its early stages
and thus most patients have widespread disease at the
time of diagnosis [4]. Despite the achievements of high
response rates with surgery followed by chemotherapy
[5,6], 75% of women ultimately die of complications asso-
ciated with disease progression. Although studies show
that the survival of early-stage disease is significantly
higher than those with advanced cancers, approximately
20% to 30% of these patients will die of their disease
[7-9]. While the 5-year survival for women presenting
with early-stage disease is approximately 90%, the major-
ity of women (75%) are diagnosed with late stage disease
(stage III or stage IV) and have a 5-year survival of less
than 30% [10]. Mortality might be reduced if the disease
is detected in the early stages [11].
The need for the development of reliable serum bio-
markers for early detection and prognostication of ovar-
ian cancer, which are both sensitive and specific,
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any medium, provided the original work is properly cited.remains a long awaited priority. Investigators are aware
of this need and the Early Detection Research Network
(EDRN) established by the National Cancer Institute has
proposed ‘guidelines’ for the development of screening
biomarkers [12]. Over the last few decades a variety of
serological tumor markers have been proposed as a sup-
plement to other non-invasive diagnostic methods [13].
A variety of biomarkers have been developed which
have the capacity to improve the dismal survival rate by
monitoring growth of ovarian cancer and by detecting
disease earlier. In the management of ovarian cancer
these biomarkers have been applied for distinguishing
malignant from benign pelvic masses, for monitoring
response to treatment, for estimating prognosis, for pre-
dicting response to individual drugs, and for detecting
primary disease at an early stage [14]. The most widely
used marker of ovarian cancer, often considered the
‘gold standard’ is CA125 [15].
The role played by CA125 has developed over the past
two decades, and presently CA125 remains the only
tumor marker that has any significant impact on the clin-
ical management of epithelial ovarian cancer [15]. Data
from several studies have demonstrated a relationship
between pre-chemotherapy serum CA125 levels [16-18]
as well as post-chemotherapy serum CA125 levels and
survival in women with epithelial ovarian malignancies
[4,19-21]. Also, the relationship between CA125 levels
and survival during chemotherapy has been evaluated in
some studies [22,23]. Furthermore, the response to treat-
ment and the clinical outcome of patients with epithelial
ovarian cancer has been related to different parameters
of evaluation of serum CA125 kinetics during early che-
motherapy, such as the nadir CA125 level [24], the time
to reach nadir level [25,26], and the most widely investi-
gated kinetic parameter the serum CA125 half-life
[22,26,27]. Similarly, some studies have evaluated the
usefulness of the CA-125 area under the curve (AUC) as
a new kinetic parameter for predicting overall survival in
patients with ovarian cancer [28,29]. Finally, studies have
evaluated the prognostic significance of pre-operative
[18,30-32] as well as post-operative serum CA125 levels
in ovarian cancer [18,31,33,34].
While there are numerous studies evaluating the rela-
tionship between CA125 assessment at a single time
point and survival as mentioned above, only a few longi-
tudinal studies have been carried out to this effect
[35,36]. Those studies found a strong independent prog-
nostic effect of a reduction in CA125 level during treat-
ment, a change in CA125 level after the first course of
chemotherapy, and CA125 half-life and nadir concentra-
tions. We carried out the present study with the goal of
further investigating the impact of serial improvement in
CA125 levels on survival in patients with ovarian cancer.
Methods
Study Sample
A retrospective chart review was performed on a conse-
cutive case series of 170 ovarian cancer patients treated
at Cancer Treatment Centers of America® (CTCA) at
Midwestern Regional Medical Center (MRMC) between
January 01 and May 06. None of these patients had
received any treatment at MRMC prior to being
enrolled in this investigation. The patients were identi-
fied from the MRMC tumor registry. All patients had
histologically confirmed diagnosis of ovarian cancer. All
patients received the same standard of care using an
integrative model combining surgery, radiation and che-
motherapy as appropriate, plus complementary therapy
consisting primarily of nutritional, psychosocial, and
spiritual support, naturopathic supplements, pain man-
agement, and physical therapy/rehabilitation.
Covariates
Covariates that were assessed for prognostic significance
were age at presentation, stage of disease at diagnosis
and prior treatment history. The prior treatment history
variable categorized patients into those who had
received definitive cancer treatment elsewhere before
coming to our institution and those who were newly
diagnosed at our institution. The only follow-up infor-
mation required was the date of death or the date of
last contact/last known to be alive. This study was
approved by the Institutional Review Board at MRMC.
Data Analysis and Statistical Methods
All data were analyzed using SPSS 11.5 (SPSS Inc., Chi-
cago, IL, USA). Based on their CA125 assessment at
baseline (study entry) and 3 months, patients were clas-
sified into 4 groups of CA125 change: 1) Normal (0-35
U/ml) at baseline and three months; 2) High (>35 U/ml)
at baseline, normal at three months; 3) Normal at base-
line, high at 3 months; 4) High at baseline and three
months. These 4 categories of CA125 change were com-
pared with each other with respect to age at presenta-
tion, stage at diagnosis and prior treatment history
using Chi-Square test or ANOVA as appropriate.
The Kaplan-Meier or product-limit method was used
to calculate survival. The log rank test statistic was used
to evaluate the equality of survival distributions across
different strata. A difference was considered to be statis-
tically significant if the p value was less than or equal to
0.05. For the purpose of evaluating the prognostic signif-
icance of CA125 at baseline, patient survival was defined
as the time interval between date of first patient visit to
the hospital and date of death from any cause or date of
last contact/last known to be alive. While for the pur-
pose of evaluating the prognostic significance of CA125
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interval between date of patient visit at 3 months from
first visit and date of death from any cause or date of
last contact/last known to be alive. Survival was also
evaluated using multivariate Cox regression analysis
after adjusting for age at presentation, prior treatment
history, and stage at diagnosis. Cox regression with
time-invariant covariates assumes that the ratio of
hazards for any two groups remains constant in propor-
tion over time. We checked this assumption by examin-
ing log-minus-log plots for categorical predictors.
Log-minus-logs plots showed that the assumptions were
met for all three categorical predictors.
Results
At the time of this analysis (June 08), 82 patients had
expired and 88 were censored, as shown in Table 1. The
cut-off date for the follow-up for all participants was
June 08. The median age at presentation was 54.2 years
(range 23.1 - 82.5 years). At baseline (study entry), 31
patients had normal serum CA125 levels (0-35 U/ml)
and 139 had high serum CA125 levels (>35 U/ml). At
3 months, 59 patients had normal serum CA125 levels
(0-35 U/ml) and 111 had high serum CA125 levels
(>35 U/ml). The median serum CA125 levels at baseline
and 3 months were 152 U/ml (range: 5 - 16200 U/ml)
and 108.5 U/ml (range: 3 - 15800 U/ml) respectively.
Of 35 newly diagnosed patients, 24 (68.6%) had stage
III or IV disease while 96 (76.8%) of 125 previously trea-
ted patients had stage III or IV disease, the difference
being statistically significant (p = 0.03). At baseline, 10
of 36 (27.8%) newly diagnosed patients had normal
CA125 levels, while 21 of 134 (15.7%) of previously
treated patients had normal CA125 levels, the difference
being statistically non-significant (p = 0.09). At baseline,
12 of 40 (30%) early-stage (stage I and II) patients had
normal CA125 levels while 19 of 120 (15.8%) late-stage
(stage III and IV) patients had normal CA125 levels, the
difference being statistically significant (p = 0.04) sug-
gesting that patients with advanced stage disease had
higher CA125 levels.
Figure 1 displays the Kaplan-Meier survival curves for
the 2 categories of serum CA125 at baseline. The med-
ian survival for patients with normal CA125 (N = 31)
was 59.2 months while for those with high CA125 (N =
139) was 18.8 months (log rank = 20.1, p < 0.0001). Fig-
u r e2d i s p l a y st h eK a p l a n - M e i e rs u r v i v a lc u r v e sf o rt h e
2 categories of serum CA125 at 3 months. The median
survival for patients with normal CA125 (N = 59) was
56.2 months while for those with high CA125 (N = 111)
was 10.7 months (log rank = 44.6, p < 0.0001).
Table 2 describes the median survival (Kaplan-Meier)
for the 4 classes of people based on their CA125 scores
at baseline and 3 months. Figure 3 displays the survival
curves for the 4 classes of change in serum CA125. In
this cohort, patients with an improved (decreased)
serum CA125 levels at 3 months (stratum 2) had a sig-
nificantly better survival than those with deteriorated
(increased) serum CA125 levels at 3 months (stratum
3). Patients with normal serum CA125 levels after
3 months (strata 1 and 2) had increased survival com-
pared to patients with high serum CA125 levels at
3 months (strata 3 and 4).
Table 3 describes the comparison between 4 cate-
gories of CA125 change with respect to age at presenta-
tion, stage at diagnosis and prior treatment history
using Chi-Square test and ANOVA as appropriate.
Seventeen of 34 (50%) patients who changed from high
at baseline to normal at 3 months (stratum 2) had pre-
viously treated disease, whereas 96 of 105 (91.4%)
patients who had high CA125 levels at both baseline
and 3 months had previously treated disease, the differ-
ence being statistically significant. In other words,
patients in stratum 4 (high to high) had a greater per-
centage of patients with previously treated disease. This
finding partly explains why patients in stratum 4 who
had high CA125 levels at baseline (N = 105) failed to
achieve an improved CA125 level at 3 months. Similarly,
a greater percentage of patients in stratum 4 had
advanced stage disease as compared to those in stratum 2.
Age at presentation did not vary across the 4 cate-
gories of CA125 change.
Table 4 describes the results of multivariate Cox
regression modeling. Multivariate time-independent Cox
modeling, after adjusting for age at presentation, stage
at diagnosis and prior treatment history found that
change in CA125 from high to normal was associated
Table 1 Patient Characteristics
Characteristic Categories Number Percent
(%)
Vital Status Expired 82 48.2
Censored
1 88 51.8
Prior Treatment Previously treated
disease
134 78.8
History Newly diagnosed 36 21.2
Stage at Diagnosis Stage I 25 14.7
Stage II 15 8.8
Stage III 106 62.4
Stage IV 14 8.2
Missing 10 5.9
Age at Presentation Mean 53.4
Median 54.2
Range 23.1 -
82.5
Baseline CA125 at study
entry
0-35 U/ml 31 18.2
>35 U/ml 139 81.8
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Figure 1 Survival Curves for 2 Categories of CA125 at Baseline.
Survival in months from 3 months after first visit
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Figure 2 Survival Curves for 2 Categories of CA125 at 3 Months.
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change in high CA125 status from baseline to 3 months.
Similarly, maintenance of normal CA125 status from
baseline to 3 months was associated with a protective
relative risk of 0.07 as compared to no change in high
CA125 status from baseline to 3 months. Age at presen-
tation, stage at diagnosis and prior treatment history
were not found to be statistically significantly associated
with survival as shown in Table 4. The overall model
was statistically significant (p < 0.001).
Discussion
CA125 is considered the ‘gold standard’ tumor marker
in ovarian cancer and has a significant impact on the
clinical management of the disease such as monitoring
of treatment response and disease progression. Several
s t u d i e sh a v ee v a l u a t e dt h ep r o g n o s t i cr o l eo fC A 1 2 5
assessments at various time points during cancer
treatment. However, there is little to no data in the lit-
erature documenting the impact of serial measurements
of CA125 on survival in ovarian cancer. As a result, the
current study was undertaken to address this important
research question. We found that patients with an
improved CA125 levels 3 months had a significantly bet-
ter survival than those with deteriorated CA125 levels at
3 months. We also found that 3 month CA125 was a
better predictor of survival as compared to baseline
CA125. These observations suggest that a patient’s
CA125 levels at 3 months after treatment might have
greater clinical significance as compared to a patient’s
CA125 levels at presentation for treatment.
In order to put our study in better context within the
existing literature, we review here two similar studies
which have examined the relationship between longitudi-
nal assessment of CA125 and survival in ovarian cancer.
A study by Markman M. et al. investigated the relationship
Table 2 Median Survival for 4 Categories of CA125 Change
Strata Baseline CA125 at study entry 3 month CA125 N Median Survival (in months) 95% CI Kaplan Meier Log-Rank P-value
1 Normal Normal 25 56.1 3.5-108.8
2 High Normal 34 35.8 33.1-38.4
3 Normal High 6 21.7 10.8-32.6 <0.0001
4 High High 105 10.1 6.2-13.9
Normal = 0-35 U/ml.
High = >35 U/ml.
Survival in months from 3 months after first visit
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Figure 3 Survival Curves for 4 Categories of CA125 Change.
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patients with advanced ovarian cancer. The serum CA125
values from 101 patients with advanced ovarian cancer
who participated in a Southwest Oncology Group trial
(SWOG 8412) were evaluated. All patients had CA 125
values available for at least 8 weeks following initiation of
chemotherapy. While pre-treatment CA125 values did not
correlate with survival, the concentration of this tumor
marker 8 weeks after initiation of therapy was a powerful
independent prognostic factor. The median survivals for
patients (n = 51) with a CA125 <35 U/ml, vs. patients
(n = 50) with a CA125 >35 U/ml, at this time point, were
26 months and 15 months, respectively (P = 0.0001).
Furthermore, women with serum CA125 values <50%
of their pre-treatment concentration at 8 weeks experi-
enced a median survival of 21 months, compared to only
10 months for individuals with tumor marker levels >50%
of their baseline value (P = 0.0003). The study concluded
that the reduction in the serum CA125 concentration over
the initial two cycles of platinum-based chemotherapy is a
powerful independent predictor of survival for patients
with suboptimal stage III or IV ovarian cancer [35].
Another study by Riedinger JM et al. assessed the
prognostic value of the CA125 change after the first and
the second courses of induction chemotherapy in 494
patients with epithelial ovarian cancer. CA125 determi-
nation of all patients was carried out before each cycle
of chemotherapy (on average 3 weeks) and different bio-
logical variables derived from CA125 kinetics during the
first two chemotherapy courses were also examined.
Changes in CA125 were classified into six groups. The
data from the study showed that early CA125 change
during the first chemotherapy course and CA125 before
the second chemotherapy course were strongly corre-
lated with survival [36].
The findings of our study, specifically the positive
impact of CA125 reduction on overall survival, compare
well with those of the above mentioned studies. The key
difference between our study and those mentioned
above revolves around the method of calculating CA125
improvements or deterioration over time. While we
used the cut-off of 35 U/ml to divide our patient popu-
lation into 4 groups based on their CA125 levels at
baseline and 3 months, the other 2 studies used percen-
tage change methodology to quantify the increase as
well as decrease in CA125 levels over time. We investi-
gated the predictive value of CA125 normalization in
addition to evaluating the absolute levels at baseline and
3 months after treatment. While the SWOG 8412 study
by Markman M. et al. included only patients with sub-
optimal residual stage III (defined as the presence of at
least one tumor mass >2 cm in diameter remaining
within the peritoneal cavity following initial cytoreduc-
tive surgery) or IV disease and the study by Riedinger
JM et al. included patients with stages IIc-IV disease
only, our study included patients across all disease
Table 3 Relationship between Change in CA125 and Covariates
Variable Change in CA125 from Baseline to 3 months N (%) P
Normal to Normal High to Normal Normal to High High to High
Prior Treatment History
￿ Previously treated disease 15 (60) 17 (50) 6 (100) 96 (91.4) <0.001 (chi-square)
￿ Newly diagnosed 10 (40) 17 (50) 0 (0) 9 (8.6)
Stage at Diagnosis
￿ Stage I 10 (40) 4 (14.3) 0 (0) 11 (10.9)
￿ Stage II 2 (8) 6 (21.4) 0 (0) 7 (6.9) 0.009 (chi- square)
￿ Stage III 11 (44) 15 (53.6) 5 (83.3) 75 (74.3)
￿ Stage IV 2 (8) 3 (10.7) 1 (16.7) 8 (7.9)
Mean (Standard Deviation)
Age at presentation 52.3 (12.9) 55.4 (11.5) 54.1 (6.3) 52.9 (10.2) 0.67 (ANOVA)
Table 4 Multivariate Cox Proportional Hazard Model
Independent
Variable
Unit of increase RR
1 95% CI P-
value
Age at presentation 1 year 1.003 0.98,
1.03
0.78
Prior treatment
history
Newly diagnosed as
referent
1.1 0.52,
2.2
0.86
Stage at Diagnosis
￿ Stage II 0.29 0.06,
1.5
0.15
￿ Stage III Stage I as referent 1.4 0.61,
3.2
0.43
￿ Stage IV 1.7 0.57,
5.0
0.35
Change in CA125
￿ Normal to
Normal
0.07 0.02,
0.26
<0.001
￿ High to
Normal
High to High as referent 0.29 0.13,
0.65
0.003
￿ Normal to
High
0.40 0.09,
1.7
0.21
1 Relative risk (Cox proportional hazard).
N = 160.
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tion to the growing body of literature on the impact of
CA125 improvements on survival during treatment in
patients with ovarian cancer.
Some limitations of this study require acknowledg-
ment. Our study, because of its retrospective nature,
relies on data not primarily meant for research. In order
to compare CA125 response to treatment and correlate
it with survival, a homogeneous group of patients must
be evaluated. However, we evaluated a mixed population
of patients (newly diagnosed as well those who have
been treated previously). We think that restricting the
analysis to newly diagnosed patients (patients with no
prior treatment history) would have been more accurate,
since it would have allowed for evaluation of true overall
survival time i.e. time from the date of diagnosis to the
date of death. Specifically, survival time for previously
treated patients in our study is longer than measured
because of the time between their initial diagnosis and
presentation at CTCA (this primarily affected the esti-
mated survival of patients in stratum 4, since over 90%
of these patients had previously treated disease). How-
ever, doing so would have caused a significant reduction
in the sample size. Moreover, the prior treatment his-
tory variable was adjusted for in the multivariate analy-
sis. In our study, the survival time was calculated from
the day of first visit at our hospital because information
on CA125 was not always available at the time of diag-
nosis for previously treated patients. This drawback
emphasizes the need for conducting prospective studies
h a v i n gC A 1 2 5i n f o r m a t i o na v a i l a b l es i n c et h ed a t eo f
diagnosis. A majority of our patients had advanced stage
disease and had failed primary treatment elsewhere
before coming to our hospital. As a result, generalizabil-
ity of the study findings to cancer patients with early-
stage disease might be questionable. However, we have
no reasons to believe that patients with early-stage dis-
ease will display different findings. Because of the retro-
spective nature of our study and lack of information on
treatments received by our patients, the specific implica-
tions of our findings on managing therapy in ovarian
cancer patients are uncertain. Prospective studies are
needed to answer this specific question.
The utility of serum CA125 measurements in managing
therapy in ovarian cancer patients continues to be a sub-
ject of great research interest. A randomized trial was
designed by Rustin GJ. et al. to determine whether there
were benefits from early treatment based on a confirmed
elevation of CA125 levels versus delaying treatment until
clinically indicated. Patients with complete remission
after first-line platinum-based chemotherapy whose
CA125 levels exceeded twice the upper limit of normal
were randomized to either immediate treatment or to
remain having blinded CA125 measurements with
treatment commencing when clinical or symptomatic
recurrence appeared. No survival benefit from early treat-
ment based on a raised serum marker level alone was
found, and therefore it was concluded that there is no
value in the routine measurement of CA125 in the fol-
low-up of ovarian cancer patients [37]. Our study, on the
other hand, confirms that both baseline and short term
(3 months) improvement in CA125 levels is associated
with better long term survival in ovarian cancer. Thus,
the CA125 trend seems to be a useful prognostic predic-
tor at different time points along the disease trajectory
for both newly diagnosed as well as previously treated
patients. While this is no news to most clinicians, the
information about length of survival as a function of
CA125 assessment might be helpful to clinicians trying
to counsel ovarian cancer patients about prognosis, espe-
cially for patients who are well into the course of their
disease. Consequently, our findings lend support to the
importance of regular monitoring of CA125 during the
entire spectrum of treatment in ovarian cancer from
the point of view of predicting survival.
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